Medicus Pharma (MDCX) director receives 50,000 stock options at $0.36 strike

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Cathy McMorris Rodgers received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. According to the footnote, the award vests quarterly in four equal installments over one year, meaning the director earns 12,500 options every quarter until fully vested. Following this grant, she holds 50,000 stock options directly, providing equity-based compensation linked to the company’s future share performance.

Insights

Equity compensation analyst

Routine director option grant aligns pay with share performance.

The filing shows Cathy McMorris Rodgers, a director of Medicus Pharma Ltd., received stock options on 50,000 common shares at an exercise price of $0.36. The grant represents equity-based compensation rather than an open-market purchase.

The options expire on June 3, 2031 and vest quarterly in four equal installments over one year, so 12,500 options vest each quarter. This structure encourages ongoing board service and ties compensation to long-term share value without immediate cash outlay from the company.

The transaction is classified as a grant or award acquisition, with no corresponding sale or tax-withholding disposition reported. As a single award and the only transaction in this filing, it appears to be a standard part of the company’s director compensation program rather than a market-timing signal.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rodgers Cathy McMorris

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Options granted: 50,000 options Exercise price: $0.36 per share Underlying common shares: 50,000 shares +3 more

6 metrics

Options granted 50,000 options Stock Option (right to buy) grant on June 3, 2026

Exercise price $0.36 per share Conversion or exercise price for granted options

Underlying common shares 50,000 shares Common Shares underlying the stock options

Post-grant option holdings 50,000 options Total derivative shares following transaction

Option expiration date June 3, 2031 Expiration of stock option grant

Vesting schedule 4 quarterly installments over 1 year Footnote: vesting terms of the option

Key Terms

Stock Option (right to buy), grant/award acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 0.3600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2031-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest quarterly financial

"The option is scheduled to vest quarterly in four equal installments"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/04/2026 - 04:18 PM Accepted by SEC EDGAR 06/04/2026 - 04:17 PM Learn about SEC filing dates

FAQ

What did Medicus Pharma (MDCX) director Cathy McMorris Rodgers receive in this Form 4?

She received a grant of stock options covering 50,000 common shares of Medicus Pharma. These options are equity compensation, not an open-market purchase, and give her the right to buy shares at a fixed exercise price if the options vest and are exercised.

What is the exercise price and term of the Medicus Pharma (MDCX) stock options?

The stock options have an exercise price of $0.36 per share and an expiration date of June 3, 2031. This means she can choose to exercise vested options at $0.36 any time before they expire, subject to the award terms.

How do the Medicus Pharma (MDCX) options granted to the director vest?

The options are scheduled to vest quarterly in four equal installments over one year. This means 12,500 options vest each quarter, gradually becoming exercisable, which encourages the director’s continued service during that vesting period.

How many Medicus Pharma (MDCX) stock options does the director hold after this grant?

Following this transaction, the director holds 50,000 stock options directly. The filing shows no other derivative positions in the derivative summary, so this grant represents her reported option position as of the transaction date in this document.

Is this Medicus Pharma (MDCX) Form 4 a buy or sell signal for investors?

The Form 4 reflects a grant of stock options, not a market trade. It is classified as a grant or award acquisition, meaning the company awarded options as compensation rather than the director buying or selling shares in the open market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodgers Cathy McMorris

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		50,000		(1)	06/03/2031	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Cathy McMorris Rodgers	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)